Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies
Status:
Recruiting
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the clinical efficacy of cyclophosphamide in patients receiving a
bone marrow graft from a matched unrelated donor in overall survival, progression free
survival and cumulative incidence of acute and chronic GvHD. Thirty patients will receive
cyclophosphamide while twenty patients will receive antihuman T-lymphocyte immune globulin
(ATG).